Danaher Corporation (NYSE:DHR) Shares Bought by Impax Asset Management LTD

Impax Asset Management LTD raised its position in Danaher Corporation (NYSE:DHR) by 13.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,279,220 shares of the conglomerate’s stock after buying an additional 148,526 shares during the period. Danaher Corporation comprises 4.5% of Impax Asset Management LTD’s portfolio, making the stock its 5th largest position. Impax Asset Management LTD owned about 0.18% of Danaher Corporation worth $109,412,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DHR. Peddock Capital Advisors LLC raised its stake in shares of Danaher Corporation by 17.4% in the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock valued at $105,000 after buying an additional 181 shares during the period. ClariVest Asset Management LLC purchased a new stake in shares of Danaher Corporation during the first quarter valued at $157,000. Motco increased its stake in shares of Danaher Corporation by 26.7% in the first quarter. Motco now owns 1,848 shares of the conglomerate’s stock valued at $158,000 after buying an additional 390 shares in the last quarter. Baystate Wealth Management LLC increased its stake in shares of Danaher Corporation by 3.3% in the first quarter. Baystate Wealth Management LLC now owns 1,900 shares of the conglomerate’s stock valued at $163,000 after buying an additional 60 shares in the last quarter. Finally, Integrated Investment Consultants LLC increased its stake in shares of Danaher Corporation by 22.1% in the first quarter. Integrated Investment Consultants LLC now owns 2,168 shares of the conglomerate’s stock valued at $185,000 after buying an additional 393 shares in the last quarter. Institutional investors own 76.12% of the company’s stock.

Shares of Danaher Corporation (NYSE DHR) traded down 0.05% during trading on Friday, hitting $80.87. The stock had a trading volume of 2,861,306 shares. The stock’s 50-day moving average is $82.32 and its 200-day moving average is $84.22. Danaher Corporation has a 12-month low of $75.71 and a 12-month high of $88.01. The stock has a market capitalization of $56.18 billion, a P/E ratio of 25.81 and a beta of 1.03.

Danaher Corporation (NYSE:DHR) last released its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.02. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The firm had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.50 billion. During the same period in the prior year, the company earned $0.90 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. Analysts predict that Danaher Corporation will post $3.95 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Danaher Corporation (NYSE:DHR) Shares Bought by Impax Asset Management LTD” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/19/impax-asset-management-ltd-buys-148526-shares-of-danaher-corporation-nysedhr-updated-updated.html.

Several equities research analysts have recently commented on DHR shares. Janney Montgomery Scott downgraded Danaher Corporation from a “buy” rating to a “neutral” rating in a report on Wednesday, June 7th. BidaskClub lowered Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Wells Fargo & Company reaffirmed a “market perform” rating on shares of Danaher Corporation in a research report on Saturday, July 22nd. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Danaher Corporation in a research report on Sunday, April 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Danaher Corporation in a research report on Sunday, April 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $91.76.

In other Danaher Corporation news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the sale, the insider now directly owns 155,520 shares in the company, valued at $12,718,425.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Linda P. Hefner sold 10,578 shares of the company’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $83.03, for a total value of $878,291.34. Following the sale, the director now owns 42,151 shares of the company’s stock, valued at $3,499,797.53. The disclosure for this sale can be found here. Insiders have sold 38,623 shares of company stock valued at $3,206,426 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.

About Danaher Corporation

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

What are top analysts saying about Danaher Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Danaher Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit